
US clinical-stage biopharmaceutical company Kymera Therapeutics has shared newย data regarding its oncology programmes KT-333 and KT-413, highlighting their robust dose-dependent …
AstraZenecaโs Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion

